As with everything else affected by Brexit, there are probably more questions than answers! The most important issue is funding and we can reassure all trial participants that the funding from the European Commission for MIROCALS will not be affected by the United Kingdom leaving the European Union.

The most important issue is funding and we can reassure all trial participants that the funding from the European Commission for MIROCALS will not be affected by the United Kingdom leaving the European Union.

The MIROCALS team has been focusing their attention on another important issue, which is whether Brexit could affect the supply of IL-2 to people taking part in the trial.

The trial treatment packages are prepared in the UK, so there was a potential risk that if the UK had left the EU at the end of March, it could have caused delays in distributing the drug to the clinics in France, as well as possibly increasing the cost. As IL-2 has a relatively short shelf-life, the treatment packages need to be prepared and distributed shortly before it is needed, so any delay could cause problems
The MIROCALS co-ordinating team worked hard to get answers from both the French authorities and the European Commission and have secured assurances that should maintain a consistent supply of IL-2, should the UK leave at the new departure date in October.